Rachael Sussman, MD
Urogynecology and Reconstructive Pelvic Surgery · Washington, DCNPI 1366718504
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.
Across 84 payments — averaging $37.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$634
- AbbVie$572
- Axonics, Inc.$534
- Boston Scientific$463
- Antares Pharma, Inc.$187
- Sumitomo Pharma America, Inc.$178
- plus $571 from 12 others
What the payments were for
- Food & beverage$3,139100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 5 | $634 |
| AbbVie(2 entities) | 26 | $572 |
| Axonics, Inc. | 15 | $534 |
| Boston Scientific | 5 | $463 |
| Antares Pharma, Inc. | 5 | $187 |
| Sumitomo Pharma America, Inc. | 8 | $178 |
| Innovation Technologies Inc | 1 | $144 |
| Urovant Sciences Inc | 5 | $110 |
| Coloplast | 3 | $77 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $69 |
| Urogen Pharma, Inc. | 1 | $30 |
| Johnson & Johnson | 1 | $26 |
| Procept Biorobotics Corporation | 1 | $24 |
| Dentsply IH AB | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Valencia Technologies Corporation | 1 | $17 |
| Millicent US Inc | 1 | $15 |
| Cook Medical LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 364 | $353,504 |
| GemtesaVibegron | 302 | $324,360 |
| Estradiol | 589 | $63,700 |
| YuvafemEstradiol | 87 | $18,586 |
| Mirabegron ErMirabegron | 25 | $15,792 |
| EstringEstradiol | 29 | $15,098 |
| Trospium Chloride ErTrospium Chloride | 47 | $9,339 |
| ImvexxyEstradiol | 11 | $5,353 |
| Tamsulosin Hcl | 243 | $4,097 |
| Methenamine Hippurate | 35 | $3,708 |
| Solifenacin Succinate | 53 | $2,914 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $2,434 |
| NitrofurantoinNitrofurantoin Macrocrystal | 41 | $1,961 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 99 | $1,794 |
| Oxybutynin Chloride ErOxybutynin Chloride | 61 | $1,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $22 | $353,504364 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $178 | $324,360302 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Washington
- Cheryl IglesiaWashington$9K
- Andrew SokolWashington$9K
- Shannon LambWashington$7K
- Charelle Carter-BrooksWashington$7K
- Lee RichterWashington$7K
- Abigail DavenportWashington$6K
- Moiuri SiddiqueWashington$4K
- Alexis DieterWashington$3K
- Helen ZhangWashington$3K
- Tatiana SansesWashington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.